Joel Beatty
Stock Analyst at Baird
(4.44)
# 385
Out of 4,667 analysts
179
Total ratings
45.97%
Success rate
27.81%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $154 → $162 | $119.24 | +35.86% | 3 | Nov 18, 2024 | |
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $3 → $11 | $5.23 | +110.33% | 4 | Nov 18, 2024 | |
| IMMP Immutep | Maintains: Outperform | $6 → $7 | $1.96 | +257.14% | 5 | Nov 15, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $112 → $116 | $94.60 | +22.62% | 3 | Nov 13, 2024 | |
| NGNE Neurogene | Maintains: Outperform | $54 → $72 | $15.33 | +369.67% | 2 | Nov 12, 2024 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $44 → $48 | $41.96 | +14.39% | 12 | Nov 8, 2024 | |
| ARGX argenx SE | Downgrades: Neutral | $515 → $650 | $591.82 | +9.83% | 5 | Nov 1, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $72 → $65 | $62.56 | +3.90% | 5 | Oct 30, 2024 | |
| CTNM Contineum Therapeutics | Initiates: Outperform | $32 | $13.65 | +134.43% | 1 | Oct 22, 2024 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $240 → $175 | $119.00 | +47.06% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $9 | $4.91 | +83.30% | 4 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $10 | $9.08 | +10.13% | 3 | Sep 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $6.08 | +163.16% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $112 → $127 | $94.81 | +33.95% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $58 | $20.77 | +179.25% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $38 | $27.91 | +36.15% | 2 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $60 | $59.77 | +0.38% | 2 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $46.40 | +55.17% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $27 | $7.52 | +259.04% | 1 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $20 | $2.29 | +773.36% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $16.27 | +72.10% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $117 | $73.68 | +58.79% | 1 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $3.99 | +12.78% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $103 | $85.64 | +20.27% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $22.64 | +10.42% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $2.59 | +247.49% | 2 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $15.95 | +75.55% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $4.56 | +250.88% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.88 | +695.45% | 1 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $1.71 | -26.90% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $12.73 | +245.64% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $18.71 | +209.99% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $25.54 | -6.03% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $18 | $2.41 | +646.89% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $16.17 | +11.32% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $2.53 | +137.15% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $46 → $31 | $9.77 | +217.46% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $6.74 | +315.43% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $248.79 | -29.66% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $4.90 | +185.71% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $110.86 | -2.58% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $35.40 | +120.34% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $20 | $0.51 | +3,837.01% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $6 | $0.49 | +1,113.59% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $0.34 | +4,306.58% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.41 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $8.06 | +86.10% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $120 | $1.19 | +9,984.03% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $15.91 | +19.42% | 3 | Nov 10, 2017 |
Jazz Pharmaceuticals
Nov 18, 2024
Maintains: Outperform
Price Target: $154 → $162
Current: $119.24
Upside: +35.86%
Amylyx Pharmaceuticals
Nov 18, 2024
Upgrades: Outperform
Price Target: $3 → $11
Current: $5.23
Upside: +110.33%
Immutep
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $1.96
Upside: +257.14%
Axsome Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $112 → $116
Current: $94.60
Upside: +22.62%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $54 → $72
Current: $15.33
Upside: +369.67%
PTC Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $44 → $48
Current: $41.96
Upside: +14.39%
argenx SE
Nov 1, 2024
Downgrades: Neutral
Price Target: $515 → $650
Current: $591.82
Upside: +9.83%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $62.56
Upside: +3.90%
Contineum Therapeutics
Oct 22, 2024
Initiates: Outperform
Price Target: $32
Current: $13.65
Upside: +134.43%
e.l.f. Beauty
Oct 21, 2024
Maintains: Outperform
Price Target: $240 → $175
Current: $119.00
Upside: +47.06%
Oct 9, 2024
Maintains: Neutral
Price Target: $13 → $9
Current: $4.91
Upside: +83.30%
Sep 5, 2024
Maintains: Neutral
Price Target: $8 → $10
Current: $9.08
Upside: +10.13%
Sep 4, 2024
Initiates: Outperform
Price Target: $16
Current: $6.08
Upside: +163.16%
Aug 2, 2024
Maintains: Outperform
Price Target: $112 → $127
Current: $94.81
Upside: +33.95%
Jul 26, 2024
Initiates: Outperform
Price Target: $58
Current: $20.77
Upside: +179.25%
Jul 25, 2024
Maintains: Outperform
Price Target: $37 → $38
Current: $27.91
Upside: +36.15%
Jul 11, 2024
Maintains: Outperform
Price Target: $36 → $60
Current: $59.77
Upside: +0.38%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $46.40
Upside: +55.17%
May 28, 2024
Initiates: Outperform
Price Target: $27
Current: $7.52
Upside: +259.04%
May 15, 2024
Maintains: Outperform
Price Target: $45 → $20
Current: $2.29
Upside: +773.36%
May 9, 2024
Maintains: Outperform
Price Target: $31 → $28
Current: $16.27
Upside: +72.10%
May 1, 2024
Initiates: Outperform
Price Target: $117
Current: $73.68
Upside: +58.79%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $3.99
Upside: +12.78%
Apr 17, 2024
Maintains: Outperform
Price Target: $83 → $103
Current: $85.64
Upside: +20.27%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $22.64
Upside: +10.42%
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $2.59
Upside: +247.49%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $15.95
Upside: +75.55%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $4.56
Upside: +250.88%
May 23, 2023
Initiates: Outperform
Price Target: $7
Current: $0.88
Upside: +695.45%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $1.71
Upside: -26.90%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $12.73
Upside: +245.64%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $18.71
Upside: +209.99%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $25.54
Upside: -6.03%
Nov 18, 2022
Maintains: Outperform
Price Target: $25 → $18
Current: $2.41
Upside: +646.89%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $16.17
Upside: +11.32%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $2.53
Upside: +137.15%
Jun 1, 2022
Maintains: Outperform
Price Target: $46 → $31
Current: $9.77
Upside: +217.46%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $6.74
Upside: +315.43%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $248.79
Upside: -29.66%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $4.90
Upside: +185.71%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $110.86
Upside: -2.58%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $35.40
Upside: +120.34%
Apr 6, 2020
Maintains: Buy
Price Target: $28 → $20
Current: $0.51
Upside: +3,837.01%
Apr 1, 2020
Maintains: Buy
Price Target: $24 → $6
Current: $0.49
Upside: +1,113.59%
Mar 26, 2020
Maintains: Buy
Price Target: $16 → $15
Current: $0.34
Upside: +4,306.58%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $2.41
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $8.06
Upside: +86.10%
Aug 17, 2018
Maintains: Neutral
Price Target: $240 → $120
Current: $1.19
Upside: +9,984.03%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $15.91
Upside: +19.42%